The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures.
In primary human and porcine hepatocyte cultures, we investigated the relationship between metabolism and cytotoxicity of troglitazone. Treatment of human hepatocytes for 2 h with 10, 20, 25, 35, and 50 microM troglitazone in protein-free medium resulted in concentration-dependent decreases in total protein synthesis. Decreases at 10 and 20 microM were reversible by 24 h, however protein synthesis did not recover at concentrations >/=25 microM. Troglitazone at 50 microM caused cellular death. In porcine hepatocytes, 100 microM troglitazone was lethal, whereas at 50 microM, protein synthesis completely recovered by 24 h. Recovery in protein synthesis was associated with metabolism of parent drug, whereas toxicity correlated (r(2) = 0.82) with accumulation of unmetabolized troglitazone. By 1 h, in human hepatocytes, troglitazone was metabolized to similar amounts of sulfate and quinone metabolites with little glucuronide detected. In contrast, porcine hepatocytes metabolized troglitazone to the similar amounts of glucuronide and the quinone metabolites with little sulfate detected. Exposure of human hepatocytes to a combination of 10 microM troglitazone and 10 microM 2,4-dichloro-4-nitrophenol resulted in a 70% decrease in protein synthesis, associated with 90% inhibition in the formation of troglitazone sulfate, a 4-fold increase in unmetabolized troglitazone, and no effect on formation of the quinone metabolite. Treatment with a combination of acetaminophen or phenobarbital with 20 microM troglitazone resulted in sustained decrease in protein synthesis associated with inhibition of sulfation and accumulation of troglitazone. These results suggest that inhibition of troglitazone sulfation may result in increased hepatotoxicity due to exposure to parent drug, or increased metabolism by alternate pathways.
Kostrubsky
V E
VE
University of Pittsburgh Medical Center, Department of Pathology, Pittsburgh, Pennsylvania, USA. vsevolod.kostrubsky@pfizer.com
Sinclair
J F
JF
Ramachandran
V
V
Venkataramanan
R
R
Wen
Y H
YH
Kindt
E
E
Galchev
V
V
Rose
K
K
Sinz
M
M
Strom
S C
SC
D000082:Acetaminophen / Q000494:pharmacology; D000818:Animals; D002478:Cells, Cultured; D002839:Chromans / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D022781:Hepatocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D009596:Nitrophenols / Q000494:pharmacology; D010416:Pentachlorophenol / Q000494:pharmacology; D010634:Phenobarbital / Q000494:pharmacology; D014176:Protein Biosynthesis; D011506:Proteins / Q000187:drug effects; D013552:Swine; D013844:Thiazoles / Q000494:pharmacology*; D045162:Thiazolidinediones; D000077288:Troglitazone
D002839:Chromans; D009596:Nitrophenols; D011506:Proteins; D013844:Thiazoles; D045162:Thiazolidinediones; D000082:Acetaminophen; C015802:2,6-dichloro-4-nitrophenol; D010416:Pentachlorophenol; D000077288:Troglitazone; D010634:Phenobarbital